淋巴细胞-话题@MedSci

#淋巴细胞#

495篇内容 | 7163人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1302126, encodeId=9c2a13021265e, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=JAMA Oncology：CD8+肿瘤浸润淋巴细胞与卵巢癌生存时间的关系, objectType=article, longId=123651, objectId=92f0123651ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92f0123651ad, replyNumber=0, likeNumber=73, createdTime=2017-12-18, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92f0123651ad, moduleTitle=JAMA Oncology：CD8+肿瘤浸润淋巴细胞与卵巢癌生存时间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92f0123651ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302125, encodeId=cadf130212514, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=Lancet oncol：Venetoclax用于进行过依鲁替尼治疗的复发性/难治性慢性淋巴细胞白血病的疗效和安全性。, objectType=article, longId=123377, objectId=c3d71233e7a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3d71233e7a0, replyNumber=0, likeNumber=60, createdTime=2017-12-15, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3d71233e7a0, moduleTitle=Lancet oncol：Venetoclax用于进行过依鲁替尼治疗的复发性/难治性慢性淋巴细胞白血病的疗效和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3d71233e7a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302124, encodeId=d690130212493, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT, objectType=article, longId=123311, objectId=ff8a12331154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff8a12331154, replyNumber=0, likeNumber=49, createdTime=2017-12-15, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff8a12331154, moduleTitle=【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff8a12331154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302123, encodeId=cc7e1302123cf, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量, objectType=article, longId=123152, objectId=40001231522f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40001231522f, replyNumber=0, likeNumber=12, createdTime=2017-12-14, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40001231522f, moduleTitle=【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40001231522f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302122, encodeId=d438130212230, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, objectType=article, longId=123151, objectId=925712315133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925712315133, replyNumber=0, likeNumber=13, createdTime=2017-12-14, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925712315133, moduleTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925712315133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302121, encodeId=6c9f13021212d, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=CLIN CANCER RES：乳腺癌中的LAG-3+肿瘤浸润淋巴细胞, objectType=article, longId=122930, objectId=26df1229305b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26df1229305b, replyNumber=0, likeNumber=66, createdTime=2017-12-12, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26df1229305b, moduleTitle=CLIN CANCER RES：乳腺癌中的LAG-3+肿瘤浸润淋巴细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26df1229305b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302120, encodeId=b2501302120e7, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=Lancet oncol：肿瘤浸润淋巴细胞（TIL）与不同亚型的乳腺癌预后的关系。, objectType=article, longId=122802, objectId=53be12280299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53be12280299, replyNumber=0, likeNumber=75, createdTime=2017-12-10, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53be12280299, moduleTitle=Lancet oncol：肿瘤浸润淋巴细胞（TIL）与不同亚型的乳腺癌预后的关系。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53be12280299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302119, encodeId=1ccd1302119c1, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果, objectType=article, longId=122749, objectId=0a3a122e49ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a3a122e49ca, replyNumber=0, likeNumber=12, createdTime=2017-12-10, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a3a122e49ca, moduleTitle=【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a3a122e49ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302118, encodeId=e14a1302118e0, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, objectType=article, longId=122745, objectId=1ede122e4567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ede122e4567, replyNumber=0, likeNumber=17, createdTime=2017-12-10, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ede122e4567, moduleTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ede122e4567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302117, encodeId=7baa130211e16, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=CLIN CANCER RES：4-1BB激动剂增强胰腺癌CD8+肿瘤浸润淋巴细胞功能, objectType=article, longId=122638, objectId=17eb122638a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17eb122638a6, replyNumber=0, likeNumber=63, createdTime=2017-12-09, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17eb122638a6, moduleTitle=CLIN CANCER RES：4-1BB激动剂增强胰腺癌CD8+肿瘤浸润淋巴细胞功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17eb122638a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302116, encodeId=979e1302116a0, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=【2017 ASH】Venetoclax在复发或难治性del17p突变慢性淋巴细胞白血病临床实践中的效果评估, objectType=article, longId=122544, objectId=343112254479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=343112254479, replyNumber=0, likeNumber=53, createdTime=2017-12-08, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=343112254479, moduleTitle=【2017 ASH】Venetoclax在复发或难治性del17p突变慢性淋巴细胞白血病临床实践中的效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=343112254479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302115, encodeId=66a41302115a2, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗, objectType=article, longId=122419, objectId=91ae12241903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91ae12241903, replyNumber=0, likeNumber=14, createdTime=2017-12-07, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91ae12241903, moduleTitle=【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91ae12241903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302114, encodeId=987213021143d, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病, objectType=article, longId=122418, objectId=f1f41224182c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1f41224182c, replyNumber=0, likeNumber=13, createdTime=2017-12-07, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1f41224182c, moduleTitle=【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1f41224182c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302113, encodeId=ae071302113ae, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=Sci Rep：血小板/淋巴细胞比例在泌尿肿瘤中的预后意义, objectType=article, longId=122160, objectId=cfdf122160ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfdf122160ca, replyNumber=0, likeNumber=57, createdTime=2017-12-05, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfdf122160ca, moduleTitle=Sci Rep：血小板/淋巴细胞比例在泌尿肿瘤中的预后意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfdf122160ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302112, encodeId=ad701302112ed, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=Hepatology：B淋巴细胞阻止肝纤维化逆转，利于小鼠肝细胞癌的发生, objectType=article, longId=121127, objectId=be7f12112e14, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be7f12112e14, replyNumber=0, likeNumber=57, createdTime=2017-11-24, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be7f12112e14, moduleTitle=Hepatology：B淋巴细胞阻止肝纤维化逆转，利于小鼠肝细胞癌的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be7f12112e14)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302111, encodeId=b3c7130211126, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=JCO:基因型特异性微小残留病改善儿童急性淋巴细胞白血病分层, objectType=article, longId=120266, objectId=6634120266a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6634120266a8, replyNumber=0, likeNumber=60, createdTime=2017-11-17, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6634120266a8, moduleTitle=JCO:基因型特异性微小残留病改善儿童急性淋巴细胞白血病分层, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6634120266a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302110, encodeId=504f13021103d, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=SCI REP：血小板与淋巴细胞比值在泌尿系肿瘤患者的预后价值如何？, objectType=article, longId=119919, objectId=f7d31199198c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7d31199198c, replyNumber=0, likeNumber=50, createdTime=2017-11-15, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7d31199198c, moduleTitle=SCI REP：血小板与淋巴细胞比值在泌尿系肿瘤患者的预后价值如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7d31199198c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302109, encodeId=08be130210962, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=NCCN临床实践指南：急性淋巴细胞白血病（2017.V5）, objectType=article, longId=119204, objectId=26f311920462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26f311920462, replyNumber=0, likeNumber=16, createdTime=2017-11-09, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26f311920462, moduleTitle=NCCN临床实践指南：急性淋巴细胞白血病（2017.V5）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26f311920462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302108, encodeId=b38213021081a, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2018.V2）, objectType=article, longId=119201, objectId=1e6e119201f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e6e119201f2, replyNumber=0, likeNumber=14, createdTime=2017-11-09, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e6e119201f2, moduleTitle=NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2018.V2）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e6e119201f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302107, encodeId=c548130210ef9, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, objectTitle=2017 日本造血和淋巴组织肿瘤指南：急性淋巴细胞白血病／成淋巴细胞性淋巴瘤, objectType=article, longId=118918, objectId=7da211891852, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7da211891852, replyNumber=0, likeNumber=14, createdTime=2017-11-07, rootId=0, userName=wetgdt, userId=1e34303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7da211891852, moduleTitle=2017 日本造血和淋巴组织肿瘤指南：急性淋巴细胞白血病／成淋巴细胞性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7da211891852)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

淋巴细胞

2020-05-29

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

JAMA Oncology：CD8+肿瘤浸润淋巴细胞与卵巢癌生存时间的关系

2017-12-18

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

Lancet oncol：Venetoclax用于进行过依鲁替尼治疗的复发性/难治性慢性淋巴细胞白血病的疗效和安全性。

2017-12-15

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT

2017-12-15

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量

2017-12-14

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案

2017-12-14

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

CLIN CANCER RES：乳腺癌中的LAG-3+肿瘤浸润淋巴细胞

2017-12-12

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

Lancet oncol：肿瘤浸润淋巴细胞（TIL）与不同亚型的乳腺癌预后的关系。

2017-12-10

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果

2017-12-10

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性

2017-12-10

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

CLIN CANCER RES：4-1BB激动剂增强胰腺癌CD8+肿瘤浸润淋巴细胞功能

2017-12-09

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

【2017 ASH】Venetoclax在复发或难治性del17p突变慢性淋巴细胞白血病临床实践中的效果评估

2017-12-08

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗

2017-12-07

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病

2017-12-07

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

Sci Rep：血小板/淋巴细胞比例在泌尿肿瘤中的预后意义

2017-12-05

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

Hepatology：B淋巴细胞阻止肝纤维化逆转，利于小鼠肝细胞癌的发生

2017-11-24

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

JCO:基因型特异性微小残留病改善儿童急性淋巴细胞白血病分层

2017-11-17

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

SCI REP：血小板与淋巴细胞比值在泌尿系肿瘤患者的预后价值如何？

2017-11-15

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

NCCN临床实践指南：急性淋巴细胞白血病（2017.V5）

2017-11-09

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2018.V2）

2017-11-09

wetgdt (审核中...)

前往app查看评论内容

#淋巴细胞#

2017 日本造血和淋巴组织肿瘤指南：急性淋巴细胞白血病／成淋巴细胞性淋巴瘤

2017-11-07

科室
- - 订阅+
  - 更多科室
工具
服务